We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Technology Bridges Gap Between New Genome Data and Years of Research

By LabMedica International staff writers
Posted on 10 Sep 2009
Since the initiation of the Human Genome Project, an explosion of data has sent the science world scurrying. More...
There is a growing demand to customize genomic codes, which inventory the "ingredients for life,” but do not sufficiently clarify how those ingredients function.

A Rutgers University-Camden (NJ, USA) biochemist is addressing this knowledge gap through the creation of a database for quick "background checks” on all known enzyme functions. Because of a U.S. National Institute of Health (Bethesda, MD, USA) grant, Dr. Peter Palenchar, an assistant professor of chemistry at the University of Rutgers-Camden (NJ, USA; ), will categorize decades-worth of research on enzymes into a database, starting with those that bind to molecules that contain adenosine.

The US$200,000 grant will allow Dr. Palenchar to track and simplify what has been written about some 130 enzymes, including energy-creators adenosine triphosphate (ATP) and adenosine diphosphate (ADP). "There are 50-plus years of good data on how enzymes function, but it's a tedious process to understand the specialized language used in enzymology papers. Question is: how do you access that information quickly?” stated Dr. Palenchar. His goal is to create a standard vocabulary to describe how enzymes function for the biomedical community, particularly those who work with anticancer drugs that target enzymes. Dr. Palenchar, with assistance from Rutgers-Camden undergraduate Jason Cargill and graduate student Salvador Gomez, will not only establish this new vocabulary for an accessible database, but also assess its effectiveness in determining the accuracy of genomic codes.

To do this, the Rutgers-Camden research team will compare the genomic sequencing in two organisms that contain "functionally important” amino acids: Arabidopsis thaliana, a plant commonly known as thale cress, and Plasmodium falciparum, the pathogen that causes malaria. "There could be good evidence that these enzymes are doing something different,” noted the biochemist, who has published his research in the past in the journal Genome Biology.

According to Mr. Gomez, who is searching primary publications through online databases such as PubMed and Academic Search Premier, this research is important. "This research has given me an opportunity to do meaningful work at a higher level,” he noted. "Knowing my work will be utilized by other scientists is a great feeling.”

Dr. Palenchar has been studying enzymes for the past 10 years. He teaches biochemistry at Rutgers-Camden.

Related Links:

Rutgers University-Camden



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
hCG Whole Blood Pregnancy Test
VEDALAB hCG-CHECK-1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.